Welcome to our dedicated page for Ironwood news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood stock.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company focused on gastrointestinal (GI) and rare diseases, and its news flow reflects this specialization. Investors and followers of IRWD news will see regular updates on the performance and clinical development of its key assets, particularly LINZESS® (linaclotide) and apraglutide.
News about LINZESS often covers U.S. net sales, prescription demand trends based on IQVIA data, and changes in financial guidance related to collaboration revenue and adjusted EBITDA. Ironwood and its U.S. partner AbbVie share equally in U.S. brand collaboration profits, so quarterly and full-year results frequently highlight LINZESS commercial margin, net profit for the U.S. brand collaboration, and the impact of pricing dynamics, gross-to-net rebate reserves and healthcare policy changes.
For apraglutide, Ironwood’s news includes clinical and regulatory milestones in short bowel syndrome with intestinal failure (SBS-IF). Press releases describe data from the STARS Phase 3 trial and the STARS Extend long-term extension study, including the number of apraglutide-dosed patients achieving enteral autonomy, as well as feedback from the U.S. Food and Drug Administration on the need for a confirmatory Phase 3 trial. Updates on the timing and design of this confirmatory trial and on regulatory submissions are recurring themes.
IRWD news also covers financial guidance for LINZESS U.S. net sales, total revenue and adjusted EBITDA, along with restructuring activities, cost management efforts and strategic reorganization steps. Additional announcements address topics such as Nasdaq listing notifications, changes in the company’s independent registered public accounting firm, participation in investor and scientific conferences, and the ongoing review of strategic alternatives with financial advisors.
By following this IRWD news page, readers can track how Ironwood’s GI and rare disease programs progress over time, how financial expectations evolve, and how regulatory, commercial and strategic developments may influence the company’s outlook.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will engage in a virtual fireside chat during the 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 3:30 p.m. ET. Interested listeners can access the live webcast via the Investors section of Ironwood's website, starting 15 minutes before the event. A replay will be available for 14 days post-conference. Ironwood focuses on developing treatments for gastrointestinal diseases and is known for its linaclotide product, a leader in the U.S. market for IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong financial results for Q3 2020, driven by a 10% year-over-year increase in LINZESS net sales, totaling $241 million. The company achieved a GAAP net income of $34.4 million ($0.22 per share), significantly up from $20.6 million the previous year. However, setbacks in its pipeline prompted the termination of IW-3718 development, leading to a planned 100-employee reduction. Ironwood expects cost savings of $95 million from this restructuring. The company also raised its 2020 revenue guidance to $370-$385 million.
Ironwood Pharmaceuticals (NASDAQ: IRWD) has appointed Alexander Denner, Ph.D., to its Board of Directors effective November 9, 2020. With Dr. Denner's appointment, the Board will consist of 10 directors, eight of whom are independent. Julie McHugh, Board Chair, emphasized Dr. Denner's extensive healthcare investment experience as a valuable asset for advancing gastrointestinal medicines and enhancing shareholder value. Dr. Denner is the founding partner of Sarissa Capital Management LP and has a notable history of leadership in healthcare companies.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will host its third quarter 2020 investor update conference call on November 5, 2020, at 4:30 p.m. Eastern Time. Participants can dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) to join the call using conference ID 2794527. A replay will be available starting the same day at 7:30 p.m. ET through November 19 at (800) 585-8367 (U.S. and Canada). Ironwood is focused on developing therapies for gastrointestinal diseases, notably linaclotide for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced disappointing results from its Phase III trial IW-3718-302 for IW-3718, which failed to meet primary endpoints for treating refractory gastroesophageal reflux disease (GERD). Following this, Ironwood will discontinue IW-3718's development and halt enrollment in another related trial. The company plans to reduce its workforce by 35%, saving over $95 million, but incur one-time costs of up to $12 million linked to the layoffs. Ironwood remains focused on maximizing LINZESS, its leading GI medication.